nodes	percent_of_prediction	percent_of_DWPC	metapath
Aripiprazole—ABCB1—Vismodegib—skin cancer	0.0547	0.142	CbGbCtD
Aripiprazole—CYP3A4—Imiquimod—skin cancer	0.0473	0.123	CbGbCtD
Aripiprazole—CYP3A4—Temozolomide—skin cancer	0.0473	0.123	CbGbCtD
Aripiprazole—CYP2D6—Vemurafenib—skin cancer	0.0408	0.106	CbGbCtD
Aripiprazole—CYP3A4—Vismodegib—skin cancer	0.0328	0.0852	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Docetaxel—skin cancer	0.0304	0.079	CbGbCtD
Aripiprazole—CYP3A7—Docetaxel—skin cancer	0.0304	0.079	CbGbCtD
Aripiprazole—ABCB1—Dactinomycin—skin cancer	0.0288	0.0747	CbGbCtD
Aripiprazole—CYP3A4—Vemurafenib—skin cancer	0.0259	0.0673	CbGbCtD
Aripiprazole—CYP3A5—Docetaxel—skin cancer	0.0228	0.0593	CbGbCtD
Aripiprazole—DRD5—eyelid—skin cancer	0.017	0.131	CbGeAlD
Aripiprazole—ABCB1—Docetaxel—skin cancer	0.0148	0.0386	CbGbCtD
Aripiprazole—CYP3A4—Docetaxel—skin cancer	0.0089	0.0231	CbGbCtD
Aripiprazole—CHRM3—muscle of abdomen—skin cancer	0.0073	0.056	CbGeAlD
Aripiprazole—HRH1—nose—skin cancer	0.00564	0.0433	CbGeAlD
Aripiprazole—CHRM5—skin epidermis—skin cancer	0.00477	0.0366	CbGeAlD
Aripiprazole—DRD1—nerve—skin cancer	0.00346	0.0266	CbGeAlD
Aripiprazole—HTR3A—nerve—skin cancer	0.00335	0.0257	CbGeAlD
Aripiprazole—H1F0—hair follicle—skin cancer	0.00294	0.0225	CbGeAlD
Aripiprazole—HTR2A—hindlimb—skin cancer	0.00222	0.017	CbGeAlD
Aripiprazole—HTR1B—blood vessel—skin cancer	0.0022	0.0169	CbGeAlD
Aripiprazole—HTR7—nerve—skin cancer	0.00216	0.0166	CbGeAlD
Aripiprazole—HTR1D—blood vessel—skin cancer	0.00213	0.0164	CbGeAlD
Aripiprazole—DRD2—nerve—skin cancer	0.00205	0.0157	CbGeAlD
Aripiprazole—H1F0—nipple—skin cancer	0.00199	0.0153	CbGeAlD
Aripiprazole—H1F0—neck—skin cancer	0.00197	0.0151	CbGeAlD
Aripiprazole—HTR2A—appendage—skin cancer	0.0019	0.0146	CbGeAlD
Aripiprazole—HTR7—endothelium—skin cancer	0.00184	0.0141	CbGeAlD
Aripiprazole—HTR7—blood vessel—skin cancer	0.0017	0.013	CbGeAlD
Aripiprazole—CHRM5—epithelium—skin cancer	0.00155	0.0119	CbGeAlD
Aripiprazole—CHRM5—skin of body—skin cancer	0.00148	0.0113	CbGeAlD
Aripiprazole—H1F0—connective tissue—skin cancer	0.00141	0.0108	CbGeAlD
Aripiprazole—HTR1E—head—skin cancer	0.00141	0.0108	CbGeAlD
Aripiprazole—HTR2A—nerve—skin cancer	0.00135	0.0104	CbGeAlD
Aripiprazole—DRD5—lymphoid tissue—skin cancer	0.00133	0.0102	CbGeAlD
Aripiprazole—DRD5—female reproductive system—skin cancer	0.00129	0.00987	CbGeAlD
Aripiprazole—H1F0—skin of body—skin cancer	0.00128	0.00978	CbGeAlD
Aripiprazole—CHRM4—head—skin cancer	0.00123	0.00947	CbGeAlD
Aripiprazole—HTR7—neck—skin cancer	0.00122	0.00933	CbGeAlD
Aripiprazole—H1F0—mammalian vulva—skin cancer	0.00116	0.00892	CbGeAlD
Aripiprazole—HTR2A—endothelium—skin cancer	0.00115	0.00882	CbGeAlD
Aripiprazole—DRD3—head—skin cancer	0.00115	0.0088	CbGeAlD
Aripiprazole—KCNH2—nipple—skin cancer	0.00114	0.00878	CbGeAlD
Aripiprazole—ADRA2C—nipple—skin cancer	0.00113	0.00866	CbGeAlD
Aripiprazole—HTR6—head—skin cancer	0.0011	0.00847	CbGeAlD
Aripiprazole—HTR1D—connective tissue—skin cancer	0.00109	0.00839	CbGeAlD
Aripiprazole—DRD5—head—skin cancer	0.00108	0.00825	CbGeAlD
Aripiprazole—ADRB1—connective tissue—skin cancer	0.00106	0.00816	CbGeAlD
Aripiprazole—HTR2A—blood vessel—skin cancer	0.00106	0.00813	CbGeAlD
Aripiprazole—H1F0—lymphoid tissue—skin cancer	0.00103	0.00792	CbGeAlD
Aripiprazole—H1F0—female reproductive system—skin cancer	0.000996	0.00764	CbGeAlD
Aripiprazole—CHRM5—head—skin cancer	0.000965	0.0074	CbGeAlD
Aripiprazole—HTR2B—skin of body—skin cancer	0.000919	0.00705	CbGeAlD
Aripiprazole—HRH1—nipple—skin cancer	0.000918	0.00704	CbGeAlD
Aripiprazole—ADRA2A—nipple—skin cancer	0.000901	0.00691	CbGeAlD
Aripiprazole—ADRA1B—head—skin cancer	0.000882	0.00676	CbGeAlD
Aripiprazole—HTR7—connective tissue—skin cancer	0.000872	0.00669	CbGeAlD
Aripiprazole—H1F0—head—skin cancer	0.000832	0.00638	CbGeAlD
Aripiprazole—HTR7—epithelium—skin cancer	0.000827	0.00635	CbGeAlD
Aripiprazole—DRD1—head—skin cancer	0.000822	0.0063	CbGeAlD
Aripiprazole—ADRA1A—epithelium—skin cancer	0.000798	0.00612	CbGeAlD
Aripiprazole—HTR1B—female reproductive system—skin cancer	0.000797	0.00611	CbGeAlD
Aripiprazole—HTR3A—head—skin cancer	0.000794	0.00609	CbGeAlD
Aripiprazole—HTR1D—female reproductive system—skin cancer	0.000772	0.00592	CbGeAlD
Aripiprazole—HTR2C—female reproductive system—skin cancer	0.000764	0.00586	CbGeAlD
Aripiprazole—HTR2A—neck—skin cancer	0.000758	0.00582	CbGeAlD
Aripiprazole—ADRB1—female reproductive system—skin cancer	0.00075	0.00575	CbGeAlD
Aripiprazole—SLC6A4—female reproductive system—skin cancer	0.000724	0.00556	CbGeAlD
Aripiprazole—CHRM1—female reproductive system—skin cancer	0.000722	0.00553	CbGeAlD
Aripiprazole—HTR2B—female reproductive system—skin cancer	0.000718	0.00551	CbGeAlD
Aripiprazole—ABCB1—blood vessel—skin cancer	0.000695	0.00533	CbGeAlD
Aripiprazole—HTR1B—head—skin cancer	0.000666	0.00511	CbGeAlD
Aripiprazole—CHRM2—head—skin cancer	0.000662	0.00508	CbGeAlD
Aripiprazole—ADRA2C—mammalian vulva—skin cancer	0.00066	0.00506	CbGeAlD
Aripiprazole—HRH1—connective tissue—skin cancer	0.000651	0.00499	CbGeAlD
Aripiprazole—CHRM3—female reproductive system—skin cancer	0.000646	0.00495	CbGeAlD
Aripiprazole—HTR1D—head—skin cancer	0.000645	0.00494	CbGeAlD
Aripiprazole—ADRA2A—connective tissue—skin cancer	0.000639	0.0049	CbGeAlD
Aripiprazole—HTR2C—head—skin cancer	0.000638	0.0049	CbGeAlD
Aripiprazole—ADRB1—head—skin cancer	0.000626	0.0048	CbGeAlD
Aripiprazole—HRH1—epithelium—skin cancer	0.000618	0.00474	CbGeAlD
Aripiprazole—ADRA1A—lymphoid tissue—skin cancer	0.000615	0.00471	CbGeAlD
Aripiprazole—HTR7—female reproductive system—skin cancer	0.000615	0.00471	CbGeAlD
Aripiprazole—SLC6A4—head—skin cancer	0.000605	0.00464	CbGeAlD
Aripiprazole—CHRM1—head—skin cancer	0.000603	0.00462	CbGeAlD
Aripiprazole—HTR2B—head—skin cancer	0.0006	0.0046	CbGeAlD
Aripiprazole—H1F0—lymph node—skin cancer	0.000583	0.00447	CbGeAlD
Aripiprazole—KCNH2—female reproductive system—skin cancer	0.000573	0.00439	CbGeAlD
Aripiprazole—HTR2A—connective tissue—skin cancer	0.000544	0.00417	CbGeAlD
Aripiprazole—CHRM3—head—skin cancer	0.000539	0.00414	CbGeAlD
Aripiprazole—HTR1A—head—skin cancer	0.000537	0.00412	CbGeAlD
Aripiprazole—HRH1—mammalian vulva—skin cancer	0.000536	0.00411	CbGeAlD
Aripiprazole—ADRA2A—mammalian vulva—skin cancer	0.000526	0.00404	CbGeAlD
Aripiprazole—HTR2A—epithelium—skin cancer	0.000516	0.00396	CbGeAlD
Aripiprazole—HTR7—head—skin cancer	0.000514	0.00394	CbGeAlD
Aripiprazole—ADRA1A—head—skin cancer	0.000495	0.0038	CbGeAlD
Aripiprazole—DRD2—head—skin cancer	0.000486	0.00372	CbGeAlD
Aripiprazole—KCNH2—head—skin cancer	0.000478	0.00367	CbGeAlD
Aripiprazole—ADRA2C—head—skin cancer	0.000472	0.00362	CbGeAlD
Aripiprazole—HRH1—female reproductive system—skin cancer	0.000459	0.00352	CbGeAlD
Aripiprazole—ADRA2A—female reproductive system—skin cancer	0.000451	0.00346	CbGeAlD
Aripiprazole—HTR2B—lymph node—skin cancer	0.00042	0.00322	CbGeAlD
Aripiprazole—HRH1—head—skin cancer	0.000383	0.00294	CbGeAlD
Aripiprazole—HTR2A—female reproductive system—skin cancer	0.000383	0.00294	CbGeAlD
Aripiprazole—ADRA2A—head—skin cancer	0.000377	0.00289	CbGeAlD
Aripiprazole—CYP3A4—female reproductive system—skin cancer	0.000355	0.00272	CbGeAlD
Aripiprazole—CYP2D6—female reproductive system—skin cancer	0.000349	0.00268	CbGeAlD
Aripiprazole—ABCB1—epithelium—skin cancer	0.000338	0.00259	CbGeAlD
Aripiprazole—KCNH2—lymph node—skin cancer	0.000335	0.00257	CbGeAlD
Aripiprazole—ADRA2C—lymph node—skin cancer	0.00033	0.00253	CbGeAlD
Aripiprazole—HTR2A—head—skin cancer	0.00032	0.00246	CbGeAlD
Aripiprazole—ABCB1—mammalian vulva—skin cancer	0.000293	0.00225	CbGeAlD
Aripiprazole—CYP2D6—head—skin cancer	0.000292	0.00224	CbGeAlD
Aripiprazole—HRH1—lymph node—skin cancer	0.000268	0.00206	CbGeAlD
Aripiprazole—ADRA2A—lymph node—skin cancer	0.000264	0.00202	CbGeAlD
Aripiprazole—ABCB1—lymphoid tissue—skin cancer	0.00026	0.002	CbGeAlD
Aripiprazole—ABCB1—female reproductive system—skin cancer	0.000251	0.00193	CbGeAlD
Aripiprazole—Headache—Vemurafenib—skin cancer	0.000226	0.000561	CcSEcCtD
Aripiprazole—Erythema—Temozolomide—skin cancer	0.000226	0.000561	CcSEcCtD
Aripiprazole—Malnutrition—Temozolomide—skin cancer	0.000226	0.000561	CcSEcCtD
Aripiprazole—Breast disorder—Docetaxel—skin cancer	0.000226	0.000559	CcSEcCtD
Aripiprazole—Discomfort—Bleomycin—skin cancer	0.000226	0.000559	CcSEcCtD
Aripiprazole—Malaise—Dactinomycin—skin cancer	0.000226	0.000559	CcSEcCtD
Aripiprazole—Cramp muscle—Docetaxel—skin cancer	0.000225	0.000557	CcSEcCtD
Aripiprazole—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000225	0.000557	CcSEcCtD
Aripiprazole—Leukopenia—Dactinomycin—skin cancer	0.000224	0.000555	CcSEcCtD
Aripiprazole—Nasopharyngitis—Docetaxel—skin cancer	0.000224	0.000554	CcSEcCtD
Aripiprazole—Dysgeusia—Temozolomide—skin cancer	0.000222	0.000549	CcSEcCtD
Aripiprazole—Asthenia—Imiquimod—skin cancer	0.000221	0.000548	CcSEcCtD
Aripiprazole—Confusional state—Bleomycin—skin cancer	0.000221	0.000547	CcSEcCtD
Aripiprazole—Alanine aminotransferase increased—Docetaxel—skin cancer	0.00022	0.000546	CcSEcCtD
Aripiprazole—Oedema—Bleomycin—skin cancer	0.000219	0.000542	CcSEcCtD
Aripiprazole—Anaphylactic shock—Bleomycin—skin cancer	0.000219	0.000542	CcSEcCtD
Aripiprazole—Back pain—Temozolomide—skin cancer	0.000219	0.000542	CcSEcCtD
Aripiprazole—Pruritus—Imiquimod—skin cancer	0.000218	0.00054	CcSEcCtD
Aripiprazole—Infection—Bleomycin—skin cancer	0.000218	0.000539	CcSEcCtD
Aripiprazole—Dysphagia—Docetaxel—skin cancer	0.000216	0.000535	CcSEcCtD
Aripiprazole—Nausea—Vemurafenib—skin cancer	0.000215	0.000532	CcSEcCtD
Aripiprazole—Thrombocytopenia—Bleomycin—skin cancer	0.000214	0.000531	CcSEcCtD
Aripiprazole—Vision blurred—Temozolomide—skin cancer	0.000213	0.000528	CcSEcCtD
Aripiprazole—Myalgia—Dactinomycin—skin cancer	0.000213	0.000528	CcSEcCtD
Aripiprazole—Tremor—Temozolomide—skin cancer	0.000212	0.000525	CcSEcCtD
Aripiprazole—Alopecia—Fluorouracil—skin cancer	0.000212	0.000524	CcSEcCtD
Aripiprazole—Diarrhoea—Imiquimod—skin cancer	0.000211	0.000522	CcSEcCtD
Aripiprazole—Discomfort—Dactinomycin—skin cancer	0.00021	0.000521	CcSEcCtD
Aripiprazole—Angina pectoris—Docetaxel—skin cancer	0.00021	0.000521	CcSEcCtD
Aripiprazole—Ill-defined disorder—Temozolomide—skin cancer	0.00021	0.00052	CcSEcCtD
Aripiprazole—ABCB1—head—skin cancer	0.00021	0.00161	CbGeAlD
Aripiprazole—Anaemia—Temozolomide—skin cancer	0.000209	0.000518	CcSEcCtD
Aripiprazole—Anorexia—Bleomycin—skin cancer	0.000209	0.000517	CcSEcCtD
Aripiprazole—Erythema—Fluorouracil—skin cancer	0.000209	0.000517	CcSEcCtD
Aripiprazole—Agitation—Temozolomide—skin cancer	0.000208	0.000515	CcSEcCtD
Aripiprazole—Angioedema—Temozolomide—skin cancer	0.000207	0.000512	CcSEcCtD
Aripiprazole—Hypotension—Bleomycin—skin cancer	0.000205	0.000507	CcSEcCtD
Aripiprazole—Oedema—Dactinomycin—skin cancer	0.000204	0.000506	CcSEcCtD
Aripiprazole—Malaise—Temozolomide—skin cancer	0.000204	0.000506	CcSEcCtD
Aripiprazole—Dizziness—Imiquimod—skin cancer	0.000204	0.000505	CcSEcCtD
Aripiprazole—Vertigo—Temozolomide—skin cancer	0.000203	0.000504	CcSEcCtD
Aripiprazole—Infection—Dactinomycin—skin cancer	0.000203	0.000503	CcSEcCtD
Aripiprazole—Leukopenia—Temozolomide—skin cancer	0.000203	0.000502	CcSEcCtD
Aripiprazole—Neutropenia—Docetaxel—skin cancer	0.000202	0.0005	CcSEcCtD
Aripiprazole—Palpitations—Temozolomide—skin cancer	0.0002	0.000495	CcSEcCtD
Aripiprazole—Thrombocytopenia—Dactinomycin—skin cancer	0.0002	0.000495	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Bleomycin—skin cancer	0.0002	0.000494	CcSEcCtD
Aripiprazole—Cough—Temozolomide—skin cancer	0.000198	0.000489	CcSEcCtD
Aripiprazole—Paraesthesia—Bleomycin—skin cancer	0.000197	0.000487	CcSEcCtD
Aripiprazole—Weight increased—Docetaxel—skin cancer	0.000197	0.000487	CcSEcCtD
Aripiprazole—Vision blurred—Fluorouracil—skin cancer	0.000197	0.000487	CcSEcCtD
Aripiprazole—Convulsion—Temozolomide—skin cancer	0.000196	0.000486	CcSEcCtD
Aripiprazole—Vomiting—Imiquimod—skin cancer	0.000196	0.000485	CcSEcCtD
Aripiprazole—Weight decreased—Docetaxel—skin cancer	0.000195	0.000484	CcSEcCtD
Aripiprazole—Hypertension—Temozolomide—skin cancer	0.000195	0.000484	CcSEcCtD
Aripiprazole—Dyspnoea—Bleomycin—skin cancer	0.000195	0.000484	CcSEcCtD
Aripiprazole—Anorexia—Dactinomycin—skin cancer	0.000195	0.000482	CcSEcCtD
Aripiprazole—Rash—Imiquimod—skin cancer	0.000194	0.000481	CcSEcCtD
Aripiprazole—Dermatitis—Imiquimod—skin cancer	0.000194	0.000481	CcSEcCtD
Aripiprazole—Pneumonia—Docetaxel—skin cancer	0.000194	0.00048	CcSEcCtD
Aripiprazole—Headache—Imiquimod—skin cancer	0.000193	0.000478	CcSEcCtD
Aripiprazole—Anaemia—Fluorouracil—skin cancer	0.000193	0.000477	CcSEcCtD
Aripiprazole—Myalgia—Temozolomide—skin cancer	0.000193	0.000477	CcSEcCtD
Aripiprazole—Arthralgia—Temozolomide—skin cancer	0.000193	0.000477	CcSEcCtD
Aripiprazole—Infestation NOS—Docetaxel—skin cancer	0.000193	0.000477	CcSEcCtD
Aripiprazole—Infestation—Docetaxel—skin cancer	0.000193	0.000477	CcSEcCtD
Aripiprazole—Anxiety—Temozolomide—skin cancer	0.000192	0.000476	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000191	0.000474	CcSEcCtD
Aripiprazole—Discomfort—Temozolomide—skin cancer	0.00019	0.000472	CcSEcCtD
Aripiprazole—Decreased appetite—Bleomycin—skin cancer	0.00019	0.000472	CcSEcCtD
Aripiprazole—Acute coronary syndrome—Docetaxel—skin cancer	0.00019	0.00047	CcSEcCtD
Aripiprazole—Renal failure—Docetaxel—skin cancer	0.000189	0.000469	CcSEcCtD
Aripiprazole—Neuropathy peripheral—Docetaxel—skin cancer	0.000189	0.000468	CcSEcCtD
Aripiprazole—Myocardial infarction—Docetaxel—skin cancer	0.000189	0.000468	CcSEcCtD
Aripiprazole—Dry mouth—Temozolomide—skin cancer	0.000188	0.000467	CcSEcCtD
Aripiprazole—Stomatitis—Docetaxel—skin cancer	0.000188	0.000465	CcSEcCtD
Aripiprazole—Jaundice—Docetaxel—skin cancer	0.000188	0.000465	CcSEcCtD
Aripiprazole—Pain—Bleomycin—skin cancer	0.000187	0.000464	CcSEcCtD
Aripiprazole—Conjunctivitis—Docetaxel—skin cancer	0.000187	0.000464	CcSEcCtD
Aripiprazole—Leukopenia—Fluorouracil—skin cancer	0.000187	0.000462	CcSEcCtD
Aripiprazole—Confusional state—Temozolomide—skin cancer	0.000186	0.000461	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000186	0.000461	CcSEcCtD
Aripiprazole—Anaphylactic shock—Temozolomide—skin cancer	0.000185	0.000458	CcSEcCtD
Aripiprazole—Oedema—Temozolomide—skin cancer	0.000185	0.000458	CcSEcCtD
Aripiprazole—Infection—Temozolomide—skin cancer	0.000184	0.000455	CcSEcCtD
Aripiprazole—Nausea—Imiquimod—skin cancer	0.000183	0.000454	CcSEcCtD
Aripiprazole—Hepatobiliary disease—Docetaxel—skin cancer	0.000182	0.000451	CcSEcCtD
Aripiprazole—Epistaxis—Docetaxel—skin cancer	0.000182	0.00045	CcSEcCtD
Aripiprazole—Nervous system disorder—Temozolomide—skin cancer	0.000181	0.000449	CcSEcCtD
Aripiprazole—Thrombocytopenia—Temozolomide—skin cancer	0.000181	0.000448	CcSEcCtD
Aripiprazole—Convulsion—Fluorouracil—skin cancer	0.000181	0.000448	CcSEcCtD
Aripiprazole—Feeling abnormal—Bleomycin—skin cancer	0.00018	0.000447	CcSEcCtD
Aripiprazole—Agranulocytosis—Docetaxel—skin cancer	0.00018	0.000445	CcSEcCtD
Aripiprazole—Skin disorder—Temozolomide—skin cancer	0.000179	0.000444	CcSEcCtD
Aripiprazole—Hyperhidrosis—Temozolomide—skin cancer	0.000179	0.000442	CcSEcCtD
Aripiprazole—Chest pain—Fluorouracil—skin cancer	0.000178	0.00044	CcSEcCtD
Aripiprazole—Myalgia—Fluorouracil—skin cancer	0.000178	0.00044	CcSEcCtD
Aripiprazole—Decreased appetite—Dactinomycin—skin cancer	0.000178	0.00044	CcSEcCtD
Aripiprazole—Fatigue—Dactinomycin—skin cancer	0.000176	0.000436	CcSEcCtD
Aripiprazole—Anorexia—Temozolomide—skin cancer	0.000176	0.000436	CcSEcCtD
Aripiprazole—Discomfort—Fluorouracil—skin cancer	0.000175	0.000434	CcSEcCtD
Aripiprazole—Pain—Dactinomycin—skin cancer	0.000175	0.000433	CcSEcCtD
Aripiprazole—Urticaria—Bleomycin—skin cancer	0.000174	0.000431	CcSEcCtD
Aripiprazole—Haemoglobin—Docetaxel—skin cancer	0.000174	0.00043	CcSEcCtD
Aripiprazole—Rhinitis—Docetaxel—skin cancer	0.000173	0.000429	CcSEcCtD
Aripiprazole—Body temperature increased—Bleomycin—skin cancer	0.000173	0.000429	CcSEcCtD
Aripiprazole—Haemorrhage—Docetaxel—skin cancer	0.000173	0.000428	CcSEcCtD
Aripiprazole—Hepatitis—Docetaxel—skin cancer	0.000173	0.000428	CcSEcCtD
Aripiprazole—Hypoaesthesia—Docetaxel—skin cancer	0.000172	0.000426	CcSEcCtD
Aripiprazole—Confusional state—Fluorouracil—skin cancer	0.000172	0.000425	CcSEcCtD
Aripiprazole—Pharyngitis—Docetaxel—skin cancer	0.000172	0.000425	CcSEcCtD
Aripiprazole—Urinary tract disorder—Docetaxel—skin cancer	0.000171	0.000423	CcSEcCtD
Aripiprazole—Oedema peripheral—Docetaxel—skin cancer	0.00017	0.000422	CcSEcCtD
Aripiprazole—Oedema—Fluorouracil—skin cancer	0.00017	0.000422	CcSEcCtD
Aripiprazole—Anaphylactic shock—Fluorouracil—skin cancer	0.00017	0.000422	CcSEcCtD
Aripiprazole—Connective tissue disorder—Docetaxel—skin cancer	0.00017	0.000421	CcSEcCtD
Aripiprazole—Urethral disorder—Docetaxel—skin cancer	0.000169	0.00042	CcSEcCtD
Aripiprazole—Infection—Fluorouracil—skin cancer	0.000169	0.000419	CcSEcCtD
Aripiprazole—Feeling abnormal—Dactinomycin—skin cancer	0.000168	0.000417	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000168	0.000417	CcSEcCtD
Aripiprazole—Insomnia—Temozolomide—skin cancer	0.000167	0.000414	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Dactinomycin—skin cancer	0.000167	0.000414	CcSEcCtD
Aripiprazole—Nervous system disorder—Fluorouracil—skin cancer	0.000167	0.000413	CcSEcCtD
Aripiprazole—Thrombocytopenia—Fluorouracil—skin cancer	0.000167	0.000413	CcSEcCtD
Aripiprazole—Visual impairment—Docetaxel—skin cancer	0.000167	0.000413	CcSEcCtD
Aripiprazole—Tachycardia—Fluorouracil—skin cancer	0.000166	0.000411	CcSEcCtD
Aripiprazole—Paraesthesia—Temozolomide—skin cancer	0.000166	0.000411	CcSEcCtD
Aripiprazole—Dyspnoea—Temozolomide—skin cancer	0.000165	0.000408	CcSEcCtD
Aripiprazole—Somnolence—Temozolomide—skin cancer	0.000164	0.000407	CcSEcCtD
Aripiprazole—Dyspepsia—Temozolomide—skin cancer	0.000163	0.000403	CcSEcCtD
Aripiprazole—Anorexia—Fluorouracil—skin cancer	0.000162	0.000402	CcSEcCtD
Aripiprazole—Eye disorder—Docetaxel—skin cancer	0.000162	0.0004	CcSEcCtD
Aripiprazole—Abdominal pain—Dactinomycin—skin cancer	0.000161	0.0004	CcSEcCtD
Aripiprazole—Body temperature increased—Dactinomycin—skin cancer	0.000161	0.0004	CcSEcCtD
Aripiprazole—Hypersensitivity—Bleomycin—skin cancer	0.000161	0.0004	CcSEcCtD
Aripiprazole—Decreased appetite—Temozolomide—skin cancer	0.000161	0.000398	CcSEcCtD
Aripiprazole—Flushing—Docetaxel—skin cancer	0.00016	0.000397	CcSEcCtD
Aripiprazole—Cardiac disorder—Docetaxel—skin cancer	0.00016	0.000397	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Temozolomide—skin cancer	0.000159	0.000395	CcSEcCtD
Aripiprazole—Fatigue—Temozolomide—skin cancer	0.000159	0.000394	CcSEcCtD
Aripiprazole—Hypotension—Fluorouracil—skin cancer	0.000159	0.000394	CcSEcCtD
Aripiprazole—Pain—Temozolomide—skin cancer	0.000158	0.000391	CcSEcCtD
Aripiprazole—Constipation—Temozolomide—skin cancer	0.000158	0.000391	CcSEcCtD
Aripiprazole—Asthenia—Bleomycin—skin cancer	0.000157	0.000389	CcSEcCtD
Aripiprazole—Angiopathy—Docetaxel—skin cancer	0.000157	0.000389	CcSEcCtD
Aripiprazole—Immune system disorder—Docetaxel—skin cancer	0.000156	0.000387	CcSEcCtD
Aripiprazole—Mediastinal disorder—Docetaxel—skin cancer	0.000156	0.000386	CcSEcCtD
Aripiprazole—Chills—Docetaxel—skin cancer	0.000155	0.000384	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000155	0.000384	CcSEcCtD
Aripiprazole—Pruritus—Bleomycin—skin cancer	0.000155	0.000384	CcSEcCtD
Aripiprazole—Insomnia—Fluorouracil—skin cancer	0.000154	0.000381	CcSEcCtD
Aripiprazole—Paraesthesia—Fluorouracil—skin cancer	0.000153	0.000379	CcSEcCtD
Aripiprazole—Alopecia—Docetaxel—skin cancer	0.000153	0.000378	CcSEcCtD
Aripiprazole—Feeling abnormal—Temozolomide—skin cancer	0.000152	0.000377	CcSEcCtD
Aripiprazole—Dyspnoea—Fluorouracil—skin cancer	0.000152	0.000376	CcSEcCtD
Aripiprazole—Mental disorder—Docetaxel—skin cancer	0.000151	0.000375	CcSEcCtD
Aripiprazole—Somnolence—Fluorouracil—skin cancer	0.000151	0.000375	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Temozolomide—skin cancer	0.000151	0.000374	CcSEcCtD
Aripiprazole—Malnutrition—Docetaxel—skin cancer	0.000151	0.000373	CcSEcCtD
Aripiprazole—Erythema—Docetaxel—skin cancer	0.000151	0.000373	CcSEcCtD
Aripiprazole—Hypersensitivity—Dactinomycin—skin cancer	0.00015	0.000373	CcSEcCtD
Aripiprazole—Dyspepsia—Fluorouracil—skin cancer	0.00015	0.000371	CcSEcCtD
Aripiprazole—Decreased appetite—Fluorouracil—skin cancer	0.000148	0.000366	CcSEcCtD
Aripiprazole—Dysgeusia—Docetaxel—skin cancer	0.000147	0.000365	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000147	0.000364	CcSEcCtD
Aripiprazole—ABCB1—lymph node—skin cancer	0.000147	0.00113	CbGeAlD
Aripiprazole—Urticaria—Temozolomide—skin cancer	0.000147	0.000363	CcSEcCtD
Aripiprazole—Asthenia—Dactinomycin—skin cancer	0.000147	0.000363	CcSEcCtD
Aripiprazole—Abdominal pain—Temozolomide—skin cancer	0.000146	0.000362	CcSEcCtD
Aripiprazole—Body temperature increased—Temozolomide—skin cancer	0.000146	0.000362	CcSEcCtD
Aripiprazole—Back pain—Docetaxel—skin cancer	0.000146	0.000361	CcSEcCtD
Aripiprazole—Pain—Fluorouracil—skin cancer	0.000146	0.00036	CcSEcCtD
Aripiprazole—Muscle spasms—Docetaxel—skin cancer	0.000145	0.000358	CcSEcCtD
Aripiprazole—Feeling abnormal—Fluorouracil—skin cancer	0.00014	0.000347	CcSEcCtD
Aripiprazole—Diarrhoea—Dactinomycin—skin cancer	0.00014	0.000346	CcSEcCtD
Aripiprazole—Vomiting—Bleomycin—skin cancer	0.000139	0.000345	CcSEcCtD
Aripiprazole—Anaemia—Docetaxel—skin cancer	0.000139	0.000345	CcSEcCtD
Aripiprazole—Rash—Bleomycin—skin cancer	0.000138	0.000342	CcSEcCtD
Aripiprazole—Dermatitis—Bleomycin—skin cancer	0.000138	0.000342	CcSEcCtD
Aripiprazole—Hypersensitivity—Temozolomide—skin cancer	0.000136	0.000337	CcSEcCtD
Aripiprazole—Urticaria—Fluorouracil—skin cancer	0.000135	0.000335	CcSEcCtD
Aripiprazole—Syncope—Docetaxel—skin cancer	0.000135	0.000334	CcSEcCtD
Aripiprazole—Leukopenia—Docetaxel—skin cancer	0.000135	0.000334	CcSEcCtD
Aripiprazole—Body temperature increased—Fluorouracil—skin cancer	0.000135	0.000333	CcSEcCtD
Aripiprazole—Palpitations—Docetaxel—skin cancer	0.000133	0.000329	CcSEcCtD
Aripiprazole—Asthenia—Temozolomide—skin cancer	0.000133	0.000328	CcSEcCtD
Aripiprazole—Loss of consciousness—Docetaxel—skin cancer	0.000132	0.000328	CcSEcCtD
Aripiprazole—Cough—Docetaxel—skin cancer	0.000131	0.000325	CcSEcCtD
Aripiprazole—Pruritus—Temozolomide—skin cancer	0.000131	0.000324	CcSEcCtD
Aripiprazole—Convulsion—Docetaxel—skin cancer	0.00013	0.000323	CcSEcCtD
Aripiprazole—Nausea—Bleomycin—skin cancer	0.00013	0.000322	CcSEcCtD
Aripiprazole—Hypertension—Docetaxel—skin cancer	0.00013	0.000322	CcSEcCtD
Aripiprazole—Vomiting—Dactinomycin—skin cancer	0.00013	0.000322	CcSEcCtD
Aripiprazole—Rash—Dactinomycin—skin cancer	0.000129	0.000319	CcSEcCtD
Aripiprazole—Arthralgia—Docetaxel—skin cancer	0.000128	0.000317	CcSEcCtD
Aripiprazole—Chest pain—Docetaxel—skin cancer	0.000128	0.000317	CcSEcCtD
Aripiprazole—Myalgia—Docetaxel—skin cancer	0.000128	0.000317	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000127	0.000315	CcSEcCtD
Aripiprazole—Diarrhoea—Temozolomide—skin cancer	0.000126	0.000313	CcSEcCtD
Aripiprazole—Hypersensitivity—Fluorouracil—skin cancer	0.000125	0.000311	CcSEcCtD
Aripiprazole—Dry mouth—Docetaxel—skin cancer	0.000125	0.00031	CcSEcCtD
Aripiprazole—Confusional state—Docetaxel—skin cancer	0.000124	0.000307	CcSEcCtD
Aripiprazole—Oedema—Docetaxel—skin cancer	0.000123	0.000304	CcSEcCtD
Aripiprazole—Anaphylactic shock—Docetaxel—skin cancer	0.000123	0.000304	CcSEcCtD
Aripiprazole—Dizziness—Temozolomide—skin cancer	0.000122	0.000303	CcSEcCtD
Aripiprazole—Infection—Docetaxel—skin cancer	0.000122	0.000302	CcSEcCtD
Aripiprazole—Nausea—Dactinomycin—skin cancer	0.000121	0.0003	CcSEcCtD
Aripiprazole—Shock—Docetaxel—skin cancer	0.000121	0.000299	CcSEcCtD
Aripiprazole—Nervous system disorder—Docetaxel—skin cancer	0.00012	0.000298	CcSEcCtD
Aripiprazole—Pruritus—Fluorouracil—skin cancer	0.00012	0.000298	CcSEcCtD
Aripiprazole—Thrombocytopenia—Docetaxel—skin cancer	0.00012	0.000298	CcSEcCtD
Aripiprazole—Tachycardia—Docetaxel—skin cancer	0.00012	0.000297	CcSEcCtD
Aripiprazole—Skin disorder—Docetaxel—skin cancer	0.000119	0.000296	CcSEcCtD
Aripiprazole—Vomiting—Temozolomide—skin cancer	0.000117	0.000291	CcSEcCtD
Aripiprazole—Anorexia—Docetaxel—skin cancer	0.000117	0.00029	CcSEcCtD
Aripiprazole—Rash—Temozolomide—skin cancer	0.000116	0.000288	CcSEcCtD
Aripiprazole—Diarrhoea—Fluorouracil—skin cancer	0.000116	0.000288	CcSEcCtD
Aripiprazole—Dermatitis—Temozolomide—skin cancer	0.000116	0.000288	CcSEcCtD
Aripiprazole—Headache—Temozolomide—skin cancer	0.000116	0.000287	CcSEcCtD
Aripiprazole—Hypotension—Docetaxel—skin cancer	0.000115	0.000284	CcSEcCtD
Aripiprazole—Dizziness—Fluorouracil—skin cancer	0.000113	0.000279	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000112	0.000277	CcSEcCtD
Aripiprazole—Insomnia—Docetaxel—skin cancer	0.000111	0.000275	CcSEcCtD
Aripiprazole—Paraesthesia—Docetaxel—skin cancer	0.00011	0.000273	CcSEcCtD
Aripiprazole—Nausea—Temozolomide—skin cancer	0.00011	0.000272	CcSEcCtD
Aripiprazole—Dyspnoea—Docetaxel—skin cancer	0.00011	0.000271	CcSEcCtD
Aripiprazole—Somnolence—Docetaxel—skin cancer	0.000109	0.00027	CcSEcCtD
Aripiprazole—Vomiting—Fluorouracil—skin cancer	0.000108	0.000268	CcSEcCtD
Aripiprazole—Dyspepsia—Docetaxel—skin cancer	0.000108	0.000268	CcSEcCtD
Aripiprazole—Rash—Fluorouracil—skin cancer	0.000107	0.000266	CcSEcCtD
Aripiprazole—Dermatitis—Fluorouracil—skin cancer	0.000107	0.000266	CcSEcCtD
Aripiprazole—Decreased appetite—Docetaxel—skin cancer	0.000107	0.000264	CcSEcCtD
Aripiprazole—Headache—Fluorouracil—skin cancer	0.000107	0.000264	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Docetaxel—skin cancer	0.000106	0.000263	CcSEcCtD
Aripiprazole—Fatigue—Docetaxel—skin cancer	0.000106	0.000262	CcSEcCtD
Aripiprazole—Pain—Docetaxel—skin cancer	0.000105	0.00026	CcSEcCtD
Aripiprazole—Constipation—Docetaxel—skin cancer	0.000105	0.00026	CcSEcCtD
Aripiprazole—Feeling abnormal—Docetaxel—skin cancer	0.000101	0.000251	CcSEcCtD
Aripiprazole—Nausea—Fluorouracil—skin cancer	0.000101	0.00025	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Docetaxel—skin cancer	0.0001	0.000249	CcSEcCtD
Aripiprazole—Abdominal pain—Docetaxel—skin cancer	9.71e-05	0.000241	CcSEcCtD
Aripiprazole—Body temperature increased—Docetaxel—skin cancer	9.71e-05	0.000241	CcSEcCtD
Aripiprazole—Hypersensitivity—Docetaxel—skin cancer	9.05e-05	0.000224	CcSEcCtD
Aripiprazole—Asthenia—Docetaxel—skin cancer	8.81e-05	0.000218	CcSEcCtD
Aripiprazole—Pruritus—Docetaxel—skin cancer	8.69e-05	0.000215	CcSEcCtD
Aripiprazole—Diarrhoea—Docetaxel—skin cancer	8.41e-05	0.000208	CcSEcCtD
Aripiprazole—Dizziness—Docetaxel—skin cancer	8.12e-05	0.000201	CcSEcCtD
Aripiprazole—Vomiting—Docetaxel—skin cancer	7.81e-05	0.000193	CcSEcCtD
Aripiprazole—Rash—Docetaxel—skin cancer	7.75e-05	0.000192	CcSEcCtD
Aripiprazole—Dermatitis—Docetaxel—skin cancer	7.74e-05	0.000192	CcSEcCtD
Aripiprazole—Headache—Docetaxel—skin cancer	7.7e-05	0.000191	CcSEcCtD
Aripiprazole—Nausea—Docetaxel—skin cancer	7.3e-05	0.000181	CcSEcCtD
Aripiprazole—DRD4—Signaling by GPCR—KRAS—skin cancer	1.27e-05	0.000157	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling by GPCR—KRAS—skin cancer	1.26e-05	0.000155	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—BRAF—skin cancer	1.25e-05	0.000155	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—ERCC2—skin cancer	1.25e-05	0.000154	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—BRAF—skin cancer	1.24e-05	0.000153	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling by GPCR—KRAS—skin cancer	1.22e-05	0.00015	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling by GPCR—KRAS—skin cancer	1.2e-05	0.000149	CbGpPWpGaD
Aripiprazole—ADRA2A—Hemostasis—TP53—skin cancer	1.2e-05	0.000148	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling by GPCR—NRAS—skin cancer	1.2e-05	0.000148	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—TERT—skin cancer	1.19e-05	0.000147	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling by GPCR—NRAS—skin cancer	1.19e-05	0.000147	CbGpPWpGaD
Aripiprazole—DRD5—Signaling Pathways—NRAS—skin cancer	1.18e-05	0.000146	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—TERT—skin cancer	1.17e-05	0.000145	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—TERT—skin cancer	1.17e-05	0.000145	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—TERT—skin cancer	1.17e-05	0.000144	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—TERT—skin cancer	1.16e-05	0.000144	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—TERT—skin cancer	1.15e-05	0.000142	CbGpPWpGaD
Aripiprazole—HTR1E—Signaling Pathways—KRAS—skin cancer	1.15e-05	0.000142	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—TERT—skin cancer	1.15e-05	0.000142	CbGpPWpGaD
Aripiprazole—ADRA2A—Hemostasis—HRAS—skin cancer	1.15e-05	0.000142	CbGpPWpGaD
Aripiprazole—DRD1—Signaling by GPCR—KRAS—skin cancer	1.15e-05	0.000142	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling by GPCR—NRAS—skin cancer	1.15e-05	0.000141	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling by GPCR—NRAS—skin cancer	1.14e-05	0.000141	CbGpPWpGaD
Aripiprazole—HTR6—Signaling by GPCR—HRAS—skin cancer	1.13e-05	0.00014	CbGpPWpGaD
Aripiprazole—DRD3—Signaling by GPCR—KRAS—skin cancer	1.13e-05	0.00014	CbGpPWpGaD
Aripiprazole—HTR7—Signaling by GPCR—HRAS—skin cancer	1.13e-05	0.00014	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—BRAF—skin cancer	1.13e-05	0.000139	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling by GPCR—HRAS—skin cancer	1.12e-05	0.000139	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—BRAF—skin cancer	1.12e-05	0.000138	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling by GPCR—NRAS—skin cancer	1.11e-05	0.000137	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling by GPCR—HRAS—skin cancer	1.1e-05	0.000136	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling by GPCR—NRAS—skin cancer	1.09e-05	0.000135	CbGpPWpGaD
Aripiprazole—HTR6—Signaling by GPCR—IL6—skin cancer	1.08e-05	0.000134	CbGpPWpGaD
Aripiprazole—DRD4—Signaling by GPCR—HRAS—skin cancer	1.08e-05	0.000134	CbGpPWpGaD
Aripiprazole—HTR7—Signaling by GPCR—IL6—skin cancer	1.08e-05	0.000134	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—BRAF—skin cancer	1.08e-05	0.000133	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling by GPCR—IL6—skin cancer	1.07e-05	0.000133	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—BRAF—skin cancer	1.07e-05	0.000132	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—TERT—skin cancer	1.07e-05	0.000132	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling by GPCR—HRAS—skin cancer	1.07e-05	0.000132	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling by GPCR—IL6—skin cancer	1.05e-05	0.00013	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—BRAF—skin cancer	1.04e-05	0.000129	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—PTGS2—skin cancer	1.04e-05	0.000128	CbGpPWpGaD
Aripiprazole—DRD4—Signaling by GPCR—IL6—skin cancer	1.04e-05	0.000128	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling by GPCR—HRAS—skin cancer	1.03e-05	0.000128	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling by GPCR—KRAS—skin cancer	1.03e-05	0.000127	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—BRAF—skin cancer	1.03e-05	0.000127	CbGpPWpGaD
Aripiprazole—HTR1E—Signaling Pathways—TP53—skin cancer	1.02e-05	0.000126	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling by GPCR—HRAS—skin cancer	1.02e-05	0.000126	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling by GPCR—IL6—skin cancer	1.02e-05	0.000126	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling by GPCR—KRAS—skin cancer	1.02e-05	0.000126	CbGpPWpGaD
Aripiprazole—DRD5—Signaling Pathways—KRAS—skin cancer	1.02e-05	0.000126	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—PTGS2—skin cancer	1.01e-05	0.000124	CbGpPWpGaD
Aripiprazole—DRD2—Signaling by GPCR—NRAS—skin cancer	1.01e-05	0.000124	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—ENO2—skin cancer	1e-05	0.000124	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—NRAS—skin cancer	9.89e-06	0.000122	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling by GPCR—IL6—skin cancer	9.89e-06	0.000122	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—NRAS—skin cancer	9.87e-06	0.000122	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling by GPCR—KRAS—skin cancer	9.86e-06	0.000122	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—NRAS—skin cancer	9.84e-06	0.000122	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—NRAS—skin cancer	9.81e-06	0.000121	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling by GPCR—KRAS—skin cancer	9.81e-06	0.000121	CbGpPWpGaD
Aripiprazole—HTR1E—Signaling Pathways—HRAS—skin cancer	9.79e-06	0.000121	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling by GPCR—IL6—skin cancer	9.79e-06	0.000121	CbGpPWpGaD
Aripiprazole—DRD1—Signaling by GPCR—HRAS—skin cancer	9.74e-06	0.00012	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—NRAS—skin cancer	9.71e-06	0.00012	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—NRAS—skin cancer	9.69e-06	0.00012	CbGpPWpGaD
Aripiprazole—DRD3—Signaling by GPCR—HRAS—skin cancer	9.61e-06	0.000119	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling by GPCR—KRAS—skin cancer	9.54e-06	0.000118	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—BRAF—skin cancer	9.45e-06	0.000117	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—ERCC2—skin cancer	9.42e-06	0.000116	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling by GPCR—KRAS—skin cancer	9.39e-06	0.000116	CbGpPWpGaD
Aripiprazole—HTR1E—Signaling Pathways—IL6—skin cancer	9.37e-06	0.000116	CbGpPWpGaD
Aripiprazole—DRD1—Signaling by GPCR—IL6—skin cancer	9.32e-06	0.000115	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—BRAF—skin cancer	9.3e-06	0.000115	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—BRAF—skin cancer	9.28e-06	0.000115	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—BRAF—skin cancer	9.25e-06	0.000114	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—BRAF—skin cancer	9.22e-06	0.000114	CbGpPWpGaD
Aripiprazole—DRD3—Signaling by GPCR—IL6—skin cancer	9.2e-06	0.000114	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—NRAS—skin cancer	9.14e-06	0.000113	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—BRAF—skin cancer	9.13e-06	0.000113	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—NRAS—skin cancer	9.13e-06	0.000113	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—BRAF—skin cancer	9.11e-06	0.000113	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—NRAS—skin cancer	9.07e-06	0.000112	CbGpPWpGaD
Aripiprazole—DRD5—Signaling Pathways—TP53—skin cancer	9.06e-06	0.000112	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—NRAS—skin cancer	9e-06	0.000111	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—PTGS2—skin cancer	8.91e-06	0.00011	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—ERCC2—skin cancer	8.88e-06	0.00011	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—NRAS—skin cancer	8.88e-06	0.00011	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling by GPCR—HRAS—skin cancer	8.76e-06	0.000108	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—NRAS—skin cancer	8.74e-06	0.000108	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling by GPCR—HRAS—skin cancer	8.68e-06	0.000107	CbGpPWpGaD
Aripiprazole—DRD5—Signaling Pathways—HRAS—skin cancer	8.66e-06	0.000107	CbGpPWpGaD
Aripiprazole—DRD2—Signaling by GPCR—KRAS—skin cancer	8.65e-06	0.000107	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—NRAS—skin cancer	8.62e-06	0.000107	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—KRAS—skin cancer	8.51e-06	0.000105	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—KRAS—skin cancer	8.5e-06	0.000105	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—KRAS—skin cancer	8.47e-06	0.000105	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—BRAF—skin cancer	8.46e-06	0.000105	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—KRAS—skin cancer	8.44e-06	0.000104	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling by GPCR—IL6—skin cancer	8.38e-06	0.000104	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling by GPCR—HRAS—skin cancer	8.38e-06	0.000104	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—KRAS—skin cancer	8.36e-06	0.000103	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—NRAS—skin cancer	8.34e-06	0.000103	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—KRAS—skin cancer	8.34e-06	0.000103	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling by GPCR—HRAS—skin cancer	8.33e-06	0.000103	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling by GPCR—IL6—skin cancer	8.31e-06	0.000103	CbGpPWpGaD
Aripiprazole—DRD5—Signaling Pathways—IL6—skin cancer	8.29e-06	0.000102	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—NRAS—skin cancer	8.26e-06	0.000102	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—PTGS2—skin cancer	8.17e-06	0.000101	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling by GPCR—HRAS—skin cancer	8.11e-06	0.0001	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling by GPCR—IL6—skin cancer	8.02e-06	9.91e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling by GPCR—HRAS—skin cancer	7.98e-06	9.86e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling by GPCR—IL6—skin cancer	7.98e-06	9.86e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—NRAS—skin cancer	7.87e-06	9.72e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—KRAS—skin cancer	7.87e-06	9.72e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—KRAS—skin cancer	7.86e-06	9.71e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—KRAS—skin cancer	7.81e-06	9.64e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—NRAS—skin cancer	7.76e-06	9.59e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling by GPCR—IL6—skin cancer	7.76e-06	9.59e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—KRAS—skin cancer	7.75e-06	9.57e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—KRAS—skin cancer	7.64e-06	9.44e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling by GPCR—IL6—skin cancer	7.64e-06	9.44e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—KRAS—skin cancer	7.52e-06	9.29e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—PTGS2—skin cancer	7.49e-06	9.25e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—KRAS—skin cancer	7.42e-06	9.17e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling by GPCR—HRAS—skin cancer	7.36e-06	9.09e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—HRAS—skin cancer	7.24e-06	8.94e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—HRAS—skin cancer	7.22e-06	8.92e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—HRAS—skin cancer	7.2e-06	8.89e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—KRAS—skin cancer	7.18e-06	8.87e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—HRAS—skin cancer	7.18e-06	8.87e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—HRAS—skin cancer	7.11e-06	8.78e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—KRAS—skin cancer	7.11e-06	8.78e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—HRAS—skin cancer	7.09e-06	8.76e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—NRAS—skin cancer	7.07e-06	8.74e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling by GPCR—IL6—skin cancer	7.04e-06	8.7e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—NRAS—skin cancer	7.01e-06	8.66e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—TP53—skin cancer	6.99e-06	8.64e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—TP53—skin cancer	6.98e-06	8.63e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—TP53—skin cancer	6.94e-06	8.57e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—IL6—skin cancer	6.93e-06	8.56e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—IL6—skin cancer	6.91e-06	8.54e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—IL6—skin cancer	6.89e-06	8.51e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—IL6—skin cancer	6.87e-06	8.49e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—IL6—skin cancer	6.8e-06	8.4e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—TP53—skin cancer	6.79e-06	8.39e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—IL6—skin cancer	6.78e-06	8.38e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—KRAS—skin cancer	6.77e-06	8.37e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—NRAS—skin cancer	6.76e-06	8.36e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—NRAS—skin cancer	6.73e-06	8.32e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—HRAS—skin cancer	6.69e-06	8.26e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—TP53—skin cancer	6.68e-06	8.26e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—KRAS—skin cancer	6.68e-06	8.25e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—HRAS—skin cancer	6.68e-06	8.25e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—HRAS—skin cancer	6.63e-06	8.2e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—TP53—skin cancer	6.59e-06	8.15e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—HRAS—skin cancer	6.58e-06	8.14e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—NRAS—skin cancer	6.55e-06	8.09e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—HRAS—skin cancer	6.5e-06	8.03e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—NRAS—skin cancer	6.44e-06	7.96e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—IL6—skin cancer	6.4e-06	7.91e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—HRAS—skin cancer	6.39e-06	7.9e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—IL6—skin cancer	6.39e-06	7.9e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—TP53—skin cancer	6.38e-06	7.88e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—IL6—skin cancer	6.35e-06	7.85e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—TP53—skin cancer	6.32e-06	7.8e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—HRAS—skin cancer	6.31e-06	7.79e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—IL6—skin cancer	6.3e-06	7.79e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—IL6—skin cancer	6.22e-06	7.68e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—IL6—skin cancer	6.12e-06	7.56e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—HRAS—skin cancer	6.1e-06	7.54e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—KRAS—skin cancer	6.09e-06	7.52e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—HRAS—skin cancer	6.04e-06	7.46e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—IL6—skin cancer	6.04e-06	7.46e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—KRAS—skin cancer	6.03e-06	7.45e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—TP53—skin cancer	6.02e-06	7.44e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—NRAS—skin cancer	5.94e-06	7.34e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—TP53—skin cancer	5.94e-06	7.34e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—NRAS—skin cancer	5.84e-06	7.22e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—IL6—skin cancer	5.84e-06	7.22e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—NRAS—skin cancer	5.83e-06	7.21e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—KRAS—skin cancer	5.82e-06	7.19e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—NRAS—skin cancer	5.81e-06	7.18e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—ERCC2—skin cancer	5.81e-06	7.17e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—NRAS—skin cancer	5.79e-06	7.16e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—KRAS—skin cancer	5.79e-06	7.16e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—IL6—skin cancer	5.78e-06	7.14e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—HRAS—skin cancer	5.76e-06	7.11e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—NRAS—skin cancer	5.74e-06	7.09e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—NRAS—skin cancer	5.72e-06	7.07e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—HRAS—skin cancer	5.68e-06	7.02e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PTGS2—skin cancer	5.65e-06	6.98e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—KRAS—skin cancer	5.63e-06	6.96e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—KRAS—skin cancer	5.54e-06	6.85e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—IL6—skin cancer	5.51e-06	6.81e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—IL6—skin cancer	5.43e-06	6.72e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—TP53—skin cancer	5.41e-06	6.68e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—TP53—skin cancer	5.36e-06	6.62e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PTGS2—skin cancer	5.33e-06	6.58e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—NRAS—skin cancer	5.32e-06	6.57e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—TP53—skin cancer	5.17e-06	6.39e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—HRAS—skin cancer	5.17e-06	6.39e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—TP53—skin cancer	5.15e-06	6.36e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—HRAS—skin cancer	5.13e-06	6.33e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—KRAS—skin cancer	5.11e-06	6.32e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—KRAS—skin cancer	5.03e-06	6.22e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—KRAS—skin cancer	5.02e-06	6.2e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—TP53—skin cancer	5.01e-06	6.19e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—KRAS—skin cancer	5e-06	6.18e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—KRAS—skin cancer	4.99e-06	6.16e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—IL6—skin cancer	4.95e-06	6.12e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—HRAS—skin cancer	4.95e-06	6.12e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—KRAS—skin cancer	4.94e-06	6.1e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—TP53—skin cancer	4.93e-06	6.09e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—KRAS—skin cancer	4.93e-06	6.09e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—HRAS—skin cancer	4.92e-06	6.08e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—IL6—skin cancer	4.91e-06	6.06e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—HRAS—skin cancer	4.79e-06	5.92e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—IL6—skin cancer	4.74e-06	5.85e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—HRAS—skin cancer	4.71e-06	5.82e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—IL6—skin cancer	4.71e-06	5.82e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—IL6—skin cancer	4.58e-06	5.66e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—KRAS—skin cancer	4.58e-06	5.65e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—TP53—skin cancer	4.54e-06	5.61e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—IL6—skin cancer	4.51e-06	5.57e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—TP53—skin cancer	4.47e-06	5.52e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—TP53—skin cancer	4.46e-06	5.51e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—TP53—skin cancer	4.45e-06	5.49e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—TP53—skin cancer	4.43e-06	5.48e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—TP53—skin cancer	4.39e-06	5.42e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—TP53—skin cancer	4.38e-06	5.41e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—HRAS—skin cancer	4.35e-06	5.37e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—HRAS—skin cancer	4.28e-06	5.28e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—HRAS—skin cancer	4.27e-06	5.27e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—HRAS—skin cancer	4.25e-06	5.25e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—HRAS—skin cancer	4.24e-06	5.24e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—HRAS—skin cancer	4.2e-06	5.19e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—HRAS—skin cancer	4.19e-06	5.17e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—IL6—skin cancer	4.16e-06	5.14e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—IL6—skin cancer	4.09e-06	5.06e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—IL6—skin cancer	4.08e-06	5.05e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—IL6—skin cancer	4.07e-06	5.03e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—TP53—skin cancer	4.07e-06	5.03e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—IL6—skin cancer	4.06e-06	5.01e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—IL6—skin cancer	4.02e-06	4.96e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—IL6—skin cancer	4.01e-06	4.95e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—HRAS—skin cancer	3.89e-06	4.81e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—IL6—skin cancer	3.72e-06	4.6e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PTGS2—skin cancer	3.48e-06	4.3e-05	CbGpPWpGaD
